Daratumumab
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Daratumumab and local guidelines before prescribing.
Anti-CD38 monoclonal antibody
Mechanism
CD38 monoclonal antibody.
Uses
Multiple myeloma.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Infusion reactions, neutropenia, infection, interference with cross-matching.
Interactions
Interferes with blood group serology.
Contraindications and cautions
Hypersensitivity
Monitoring
FBC, blood group record
Pregnancy and breastfeeding
Avoid
Renal and hepatic impairment
No adjustment
Overdose and reversal
Supportive
Special advice
Notify blood bank before transfusion; premedicate; hepatitis B screening.
More from the textbook: uses, cautions and other points
- Treatment: Urgent plasma-cell-directed therapy - daratumumab with cyclophosphamide, bortezomib and dexamethasone (Dara-CyBorD) is standard first-line; autologous stem cell transplant in selected patients.
Cardiology: Cardiomyopathies - Infection prevention: aciclovir with bortezomib, carfilzomib or daratumumab; consider levofloxacin prophylaxis in the first 12 weeks of treatment (TEAMM trial); pneumococcal, influenza and COVID-19 vaccines; immunoglobulin replacement for recurrent serious infections with low IgG.
Haematology: Myeloma and Lymphoma - Treatment: treat the plasma cell clone (daratumumab with cyclophosphamide, bortezomib and dexamethasone) and support the failing organ. In cardiac amyloid avoid digoxin and non-dihydropyridine calcium-channel blockers; beta-blockers are poorly tolerated.
Haematology: Myeloma and Lymphoma - Treatment: Chemotherapy against the plasma cell clone - daratumumab with bortezomib, cyclophosphamide and dexamethasone ; stem cell transplant for some.
Renal: Glomerular Disease - Daratumumab (CD38) | Myeloma | Infusion reactions; interferes with blood compatibility testing - tell the lab before transfusion
Haematology: Anatomy Physiology and Pharmacology - Crossmatch problems in a myeloma patient on a new antibody | Daratumumab (CD38) interference
Haematology: Anatomy Physiology and Pharmacology - Induction with a bortezomib-based combination (NICE NG35: bortezomib and dexamethasone, with or without thalidomide; many centres add daratumumab).
Haematology: Myeloma and Lymphoma - Older, frail or transplant-ineligible: daratumumab-lenalidomide-dexamethasone, bortezomib-based regimens (for example with melphalan and prednisolone) or lenalidomide-dexamethasone, with dose reduction for frailty.
Haematology: Myeloma and Lymphoma
Where it is discussed in the book
- Cardiology: Cardiomyopathies (1 mention)
- Renal: Glomerular Disease (1 mention)
- Haematology: Anatomy Physiology and Pharmacology (2 mentions)
- Haematology: Myeloma and Lymphoma (6 mentions)
- Oncology: Emergencies (1 mention)
- Clinical Immunology: Biologics, immunotherapy, checkpoint toxicity and transplant immunology (2 mentions)
- Integrated cardiology chapter (1 mention)
- Pathology: Immunopathology, amyloidosis, genetic and environmental disease (1 mention)